Stocks Health care MREO
NASDAQ · Health careMereo BioPharma Group plc (MREO)
It posted a net loss of $28.1M. In fiscal 2025 capital spending exceeded operating cash flow by $31M. At June 30, 2026 it held $30.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Mereo BioPharma Group plc
- Net worth
- Mereo BioPharma Group plc has a market value (market cap) of $45.8M at the latest share price, and shareholders' equity of $28.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $500K, with a net loss of $41.9M.
- Cash flow
- In fiscal 2025 operations used $31M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Mereo BioPharma Group plc's next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Mereo BioPharma Group plc does
Mereo BioPharma Group plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MREO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $500K | -$41.9M | -$0.05 | -$31M |
| 2024 | $0 | -$43.3M | -$0.06 | -$32.8M |
| 2023 | $10M | -$29.5M | -$0.04 | -$21.1M |
| 2023 | $0 | -$42.2M | -$0.07 | -$48.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MREO ranks in Health care
Latest SEC filings
What Mereo BioPharma Group plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 19, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 11, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
- May 14, 2026
- May 12, 2026Quarterly results 8-K/A
- May 12, 2026
Insider trades
What the people running Mereo BioPharma Group plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns MREO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rubric Capital Management LP13D, may seek influence with 1 related filers | 14.2% | June 17, 2024 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 8.4% | May 15, 2026 |
| 683 Capital Management, LLC13G, passive with 2 related filers | 8.18% | January 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 61 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rubric Capital Management LP | 15,307,347 | 0 |
| 683 Capital Management, LLC | 11,777,856 | -222,144 |
| Bank of America Corp | 8,195,281 | -6 |
| Defilade Capital Management, L.P. | 7,558,756 | 0 |
| Newtyn Management, LLC | 3,000,000 | -4,079,056 |
| Tejara Capital Ltd | 2,037,520 | 0 |
| UBS Group AG | 1,447,627 | -42,501 |
| Two Sigma Investments, LP | 1,319,241 | +1,131,402 |
| EcoR1 Capital, LLC | 1,000,000 | -12,368,855 |
| Jane Street Group, LLC | 774,944 | +634,971 |
| Ishara Investments LP | 768,750 | new |
| Wealthspire Advisors, LLC | 765,000 | -31,036 |
| Citadel Advisors LLC | 444,158 | new |
| Rangeley Capital, LLC | 329,200 | 0 |
| Susquehanna International Group, Llp | 213,270 | +17,350 |
| Marshall Wace, Llp | 179,884 | -507,103 |
| XTX Topco Ltd | 174,481 | +90,012 |
| Group One Trading LLC | 167,515 | -168,312 |
| State Street Corp | 134,772 | +1,393 |
| Nomura Holdings Inc | 104,361 | new |
Insiders
Questions about MREO
What does Mereo BioPharma Group plc do?
Mereo BioPharma Group plc is a company in the Health care sector, listed on NASDAQ as MREO. Its shares trade on NASDAQ under the ticker MREO.
What is Mereo BioPharma Group plc's net worth?
Mereo BioPharma Group plc has a market value (market cap) of $45.8M at the latest share price, and shareholders' equity of $28.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Mereo BioPharma Group plc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $28.1M.
When did Mereo BioPharma Group plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from August 19, 2026.
When is Mereo BioPharma Group plc's next earnings report?
Mereo BioPharma Group plc's next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare MREO with
Follow MREO
Get an email when Mereo BioPharma Group plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Mereo BioPharma Group plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.